Latanoprost and herpes simplex keratitis.
OBJECTIVE
To report three cases in which herpes simplex keratitis developed after initiation of latanoprost therapy.


METHODS
Case report.


RESULTS
One patient with a history of herpes simplex keratitis had recurrence of herpes simplex keratitis with latanoprost treatment, resolution when latanoprost was stopped, and another recurrence when rechallenged with latanoprost. A second patient with a history of herpes simplex keratitis had bilateral recurrence with initiation of latanoprost; antiviral therapy could not eradicate herpes simplex keratitis until the latanoprost was discontinued. The third patient with latanoprost-associated herpes simplex keratitis cleared with the discontinuation of latanoprost and start of antiviral therapy; reinstitution of latanoprost with prophylactic antiviral medication kept the cornea clear, but as soon as the antiviral suppression was discontinued, herpes simplex keratitis reappeared.


CONCLUSIONS
Latanoprost, among its diverse pharmacologic effects, may mediate inflammation in the eye. Prostaglandins may be a final common pathway for stimulating recurrence of herpes simplex keratitis. Clinicians should be aware of this possible association.
Wand
M
M
Hartford Hospital, University of Connecticut School of Medicine, Farmington, USA.
Gilbert
C M
CM
Liesegang
T J
TJ
D000368:Aged; D000369:Aged, 80 and over; D003315:Cornea / Q000473:pathology / Q000821:virology*; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy; D018259:Herpesvirus 1, Human / Q000254:growth & development*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D016849:Keratitis, Herpetic / Q000473:pathology / Q000821:virology*; D000077338:Latanoprost; D008297:Male; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects* / Q000627:therapeutic use; D012008:Recurrence; D014775:Virus Activation / Q000187:drug effects*
D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost